Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News BioCardia Inc BCDA

Healthcare Biotechnology
BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and... see more

Recent & Breaking News (NDAQ:BCDA)

BioCardia Reports Second Quarter 2023 Business Highlights and Financial Results

GlobeNewswire August 9, 2023

BioCardia to Host Q2 2023 Financial Results and Corporate Update Conference Call on August 9, 2023

GlobeNewswire August 2, 2023

BioCardia Announces DSMB Recommendation to Pause New Enrollment in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial While Additional Blinded Data is Collected

GlobeNewswire July 24, 2023

BioCardia Completes Submission of CardiAMP Cell Therapy System in Heart Failure to Japan's Pharmaceutical Medical Device Agency

GlobeNewswire July 5, 2023

BioCardia Announces FDA Completes Review of Proposed Adaptive Statistical Analysis Design for Ongoing CardiAMP Cell Therapy in Heart Failure Pivotal Study

GlobeNewswire June 20, 2023

BioCardia Announces Helix(TM) Biotherapeutic Delivery Patent Issuance in Japan

GlobeNewswire June 8, 2023

BioCardia Announces Timing of the Next Data Safety Monitoring Board Meeting for the CardiAMP Cell Therapy in Heart Failure Pivotal Study

GlobeNewswire May 23, 2023

BioCardia Reports First Quarter 2023 Business Highlights and Financial Results

GlobeNewswire May 10, 2023

BioCardia Announces US Patent on Bone Marrow Derived Neurokinin-1 Receptor Positive (NK1R+) Mesenchymal Stem Cells for Therapeutic Applications

GlobeNewswire May 9, 2023

BioCardia to Host Q1 2023 Financial Results and Corporate Update Conference Call on May 10, 2023

GlobeNewswire May 3, 2023

BioCardia Presentations at Next Generation Cardiovascular Drug Development Summit Now Available

GlobeNewswire April 28, 2023

BioCardia Announces Issuance of Two Patents Related to Technology That Guides Interventional Therapies

GlobeNewswire April 4, 2023

BioCardia Reports Fourth Quarter and Full Year 2022 Business Highlights and Financial Results

GlobeNewswire March 29, 2023

BioCardia to Host 2022 Financial Results and Corporate Update Conference Call on March 29, 2023

GlobeNewswire March 16, 2023

Positive Echocardiography Data from BioCardia Phase III CardiAMP Cell Therapy Heart Failure Trial Presented at American College of Cardiology Annual Meeting

GlobeNewswire March 6, 2023

BioCardia and CellProthera Enhance Collaboration for Development of ProtheraCytes(TM) for the Treatment of Acute Myocardial Infarction in Europe and Potential Early Access for Patients

GlobeNewswire February 1, 2023

BioCardia Letter to Shareholders

GlobeNewswire December 22, 2022

BioCardia Announces $3.6 Million Private Placement of Common Stock

GlobeNewswire December 15, 2022

BioCardia Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure

Business Wire December 6, 2022

BioCardia Reports Third Quarter 2022 Business Highlights and Financial Results

GlobeNewswire November 9, 2022